InvestorsHub Logo
Followers 4
Posts 123
Boards Moderated 0
Alias Born 12/13/2008

Re: None

Thursday, 01/16/2014 10:52:44 AM

Thursday, January 16, 2014 10:52:44 AM

Post# of 5918
One of the advantages of having wide Wall Street coverage is the ability to constantly screen even the smallest tidbits of research that is put out each day. Many times firms will put out long-winded, excruciating detail that includes massive graphs and page after page of balance sheet data. Sometimes the data looks small in quantity but is actually huge in quality.

The analysts at Piper Jaffray have returned from meeting with some of the top biotechs the cover, and they have gleaned some interesting morsels that could be huge as the year wears on.

...

GW Pharmaceuticals PLC (NASDAQ: GWPH) recently entered an agreement with Ipsen, a French pharmaceutical company to promote and distribute Sativex, its controversial cannabis spray, in Latin America (excluding Mexico and the Caribbean islands). Sativex is used to treat spasticity in multiple sclerosis patients, and has been approved in 24 countries, primarily across Europe. The company also announced the pending use patent on Epidolex could extend exclusivity of the potential migraine drug until 2032. This is another cannabis related extract. The Piper Jaffray price target for the stock is $73. The Thomson/First Call target is set at $54.50. The stock closed Wednesday at $51.

...


247wallst.com/healthcare-business/2014/01/16/piper-jaffray-has-four-biotech-stocks-to-buy-with-huge-potential/#ixzz2qZJw4K8d